Cantor’s healthcare analyst Daniel Brims weighed in today with an optimistic view on MEI Pharma Inc (NASDAQ:MEIP), after the company's cancer drug failed to meet the main goal …
Roth Capital’s healthcare analyst Joseph Pantginis weighed in with a few insights on MEI Pharma (NASDAQ:MEIP), after the company provided an update from its MEI-004 Phase II study …
